

" " " "
" " " "

2

11

1

2022 1 11

2022

61

A

100,000,000

1

13.23

1,323,000,000.00

1,197,464,432.14

2022 3 17

2022 6-10

/

2022 6 7

1		150,000.00	100,000.00	26,607.12	26,607.12

2

6

2

2022

1

6

2

2022

1

2022 6-413

2

2022

2022

15

1

2022 14

6


2

11


1

(本页正文为《海通证券股份有限公司关于和元生物制药技术(上海)股份有限公司使用募集资金置换已预先投入募投项目及已支付发行费用自筹资金的核查意见》之签章页)

保荐代表人姓名:



陈恒瑞



张子慧

